MARKET

CERS

CERS

Cerus Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.28
-0.18
-2.79%
After Hours: 6.28 0 0.00% 16:00 03/03 EST
OPEN
6.38
PREV CLOSE
6.46
HIGH
6.38
LOW
6.03
VOLUME
3.04M
TURNOVER
--
52 WEEK HIGH
8.87
52 WEEK LOW
2.710
MARKET CAP
1.06B
P/E (TTM)
-17.1632
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit
Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Jefferies Virtual Global Plasma Summit on Th...
Business Wire · 8h ago
COVID-19 Convalescent Plasma Study Shows No Benefit, US NIH Stops Trial
The National Institutes of Health (NIH) has halted a trial evaluating the safety and effectiveness<
Benzinga · 12h ago
NIH halts a convalescent plasma trial in patients with mild COVID-19
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second
Seekingalpha · 1d ago
3 Small Caps for the Growth-Oriented Investor
3 Small Caps for the Growth-Oriented Investor, Stocks: SYKE,QTT,CERS, release date:Mar 02, 2021
GuruFocus.com · 1d ago
How Cathie Wood plans to navigate choppy market waters now that she manages $54 billion
Ark Invest's assets under management have ballooned to nearly $54 billion from about $3.9 billion this time last year.
CNBC.com · 5d ago
DJ Cerus Corporation's CEO Obi Greenman on Q4 2020 Results -- Earnings Call Transcript >CERS
Dow Jones · 5d ago
10-K: CERUS CORP
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations This discussion and analysis...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Cerus Q4 EPS $(0.09), Inline, Sales $33.60M Beat $32.42M Estimate
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company
Benzinga · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERS. Analyze the recent business situations of Cerus Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERS stock price target is 9.10 with a high estimate of 10.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 261
Institutional Holdings: 154.11M
% Owned: 91.61%
Shares Outstanding: 168.22M
TypeInstitutionsShares
Increased
54
6.34M
New
45
3.41M
Decreased
51
5.90M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.37%
Healthcare Equipment & Supplies
-2.63%
Key Executives
Chairman/Director
Daniel Swisher
Chief Executive Officer/President/Director
William Greenman
Chief Financial Officer/Vice President - Finance
Kevin Green
Chief Operating Officer
Vivek Jayaraman
Senior Vice President
Carol Moore
Chief Scientific Officer
Laurence Corash
Other
Richard Benjamin
Other
Chrystal Menard
Independent Director
Timothy Anderson
Independent Director
Eric Bjerkholt
Independent Director
Timothy Moore
Independent Director
Jami Nachtsheim
Independent Director
Gail Schulze
Independent Director
Frank Witney
Independent Director
Franklin Witney
  • Dividends
  • Splits
  • Insider Activity
No Data
About CERS
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.